Table 5.

Clinical Study for evaluation of Favipiravir (https://clinicaltrials.gov/ct2/results).

Clinical Trial Number	Study Description	Phase	Dose	Location
NCT04346628	Administration Favipiravir orally comparing with the Standard Supportive Care given in Subjects against Mild COVID-19	2	Day1: 1800 mg then 800 mg twice daily for the next 9 days	United States
NCT04349241	Efficacy and Safety of Favipiravir in Management of COVID-19	3	1600 mg after every 12 h loading dose on the first day followed by 1200 mg maintenance dose on day 2–10	Egypt
NCT04333589	Utilization of Favipiravir for Patients whose Nucleic Acids Changed From Negative to Positive	Not Applicable	Day 1: 1600 mg twice a day Day 2-7: 600 mg twice a day.	China
NCT04358549	Clinical Trial to Study of the Use of Favipiravir for Hospitalized patients	2	Day 1: 1800 mg BID Days 2-14: 1000 mg BID For subjects with Child-Pugh: Days 2-14: 800 mg BID plus Standard care	United States
NCT04336904	Evaluation of The safety and performance Of Favipiravir against COVID-19	3	Day 1: 1800 mg BID Days 2-14: 600 mg TID	Italy
NCT04359615	Favipiravir in Hospitalized COVID-19 Patients (FIC)	4	Not specified	Tehran, Iran
NCT04310228	Favipiravir and Tocilizumab combination	Not applicable	Favipiravir group On Day 1, 1600 mg, two times a day; from the 2nd to the 7th day, 600 mg, two times a day. Tocilizumab group 4 ~ 8 mg/kg	China